Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 05'th Nov 2025
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
07:00am, Wednesday, 29'th Oct 2025
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 16'th Oct 2025
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
11:01am, Wednesday, 15'th Oct 2025
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first pa
EyePoint Announces Pricing of Public Offering
10:43pm, Tuesday, 14'th Oct 2025
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Announces Proposed Public Offering of Common Stock
04:35pm, Tuesday, 14'th Oct 2025
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
04:01pm, Tuesday, 14'th Oct 2025
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 –
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Sep 2025
WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati
EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript
06:03pm, Tuesday, 02'nd Sep 2025
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Jay Duker - President, CEO & Director George Elston - Execut
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 26'th Aug 2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Monday, 18'th Aug 2025
WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint (EYPT) Q2 Revenue Drops 44%
04:37pm, Wednesday, 06'th Aug 2025
EyePoint (EYPT) Q2 Revenue Drops 44%
EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript
04:09pm, Wednesday, 06'th Aug 2025
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants George O. Elston - Executive VP & CFO Jay S.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
09:31am, Wednesday, 06'th Aug 2025
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.58 per share a year ago.
